Literature DB >> 20580552

NF-kappaB inducing kinase (NIK) inhibitors: identification of new scaffolds using virtual screening.

Jérémie Mortier1, Bernard Masereel, Caroline Remouchamps, Corinne Ganeff, Jacques Piette, Raphaël Frederick.   

Abstract

As a wide variety of pro-inflammatory cytokines are involved in the development of rheumatoid arthritis (RA), there is an urgent need for the discovery of novel therapeutic strategies. Among these, the inhibition of the NF-kappaB inducing kinase (NIK), a key enzyme of the NF-kappaB alternative pathway activation, represents a potential interesting approach. In fact, NIK is involved downstream of many tumor necrosis factor receptors (TNFR) like CD40, RANK or LTbetaR, implicated in the pathogenesis of RA. But, up to now, the number of reported putative NIK inhibitors is extremely limited. In this work, we report a virtual screening (VS) study combining various filters including high-throughput docking using a 3D-homology model and ranking by using different scoring functions. This work led to the identification of two molecular fragments, 4H-isoquinoline-1,3-dione (5) and 2,7-naphthydrine-1,3,6,8-tetrone (6) which inhibit NIK with an IC(50) value of 51 and 90 microM, respectively. This study opens new perspectives in the field of the NF-kappaB alternative pathway inhibition. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20580552     DOI: 10.1016/j.bmcl.2010.06.027

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  16 in total

Review 1.  From laptop to benchtop to bedside: structure-based drug design on protein targets.

Authors:  Lu Chen; John K Morrow; Hoang T Tran; Sharangdhar S Phatak; Lei Du-Cuny; Shuxing Zhang
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 2.  Protease activity of the API2-MALT1 fusion oncoprotein in MALT lymphoma development and treatment.

Authors:  Shaun Rosebeck; Peter C Lucas; Linda M McAllister-Lucas
Journal:  Future Oncol       Date:  2011-05       Impact factor: 3.404

3.  Lymphotoxin-β receptor-NIK signaling induces alternative RELB/NF-κB2 activation to promote metastatic gene expression and cell migration in head and neck cancer.

Authors:  Rita Das; Jamie Coupar; Paul E Clavijo; Anthony Saleh; Tsu-Fan Cheng; Xinping Yang; Jianhong Chen; Carter Van Waes; Zhong Chen
Journal:  Mol Carcinog       Date:  2018-11-28       Impact factor: 4.784

4.  Targeting the alternative NF-κB pathway in pancreatic cancer: a new direction for therapy?

Authors:  Peter Storz
Journal:  Expert Rev Anticancer Ther       Date:  2013-05       Impact factor: 4.512

5.  Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival.

Authors:  Stella M Ranuncolo; Stefania Pittaluga; Moses O Evbuomwan; Elaine S Jaffe; Brian A Lewis
Journal:  Blood       Date:  2012-09-11       Impact factor: 22.113

6.  Quinazoline-2,4(1H, 3H)-diones inhibit the growth of multiple human tumor cell lines.

Authors:  Xiaoli Zhou; Xilei Xie; Gang Liu
Journal:  Mol Divers       Date:  2013-01-26       Impact factor: 2.943

7.  Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB.

Authors:  Yulia N Demchenko; Leslie A Brents; Zhihong Li; Leif P Bergsagel; Lawrence R McGee; Michael W Kuehl
Journal:  Oncotarget       Date:  2014-06-30

8.  Treg engage lymphotoxin beta receptor for afferent lymphatic transendothelial migration.

Authors:  C Colin Brinkman; Daiki Iwami; Molly K Hritzo; Yanbao Xiong; Sarwat Ahmad; Thomas Simon; Keli L Hippen; Bruce R Blazar; Jonathan S Bromberg
Journal:  Nat Commun       Date:  2016-06-21       Impact factor: 14.919

9.  Ligand pose and orientational sampling in molecular docking.

Authors:  Ryan G Coleman; Michael Carchia; Teague Sterling; John J Irwin; Brian K Shoichet
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

Review 10.  Pharmacological inhibition of NF-κB-inducing kinase (NIK) with small molecules for the treatment of human diseases.

Authors:  Jing Cheng; Xuexin Feng; Zhiqiang Li; Feilong Zhou; Jin-Ming Yang; Yujun Zhao
Journal:  RSC Med Chem       Date:  2021-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.